Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated
with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.
The study investigates the effect af intervention with GLP-1-analog on risk markers of
cardiovascular disease in women with PCOS.
70 women will be included in af RCT.
Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a
beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.